Europe Long-Term Injectable Drug Delivery Market Size and Forecast (2021

Description

List of Tables

The Europe Long-Term Injectable Drug Delivery Market is projected to increase from US$ 2,462.4 Million in 2025 to US$ 5,122.2 Million by 2034. The market is anticipated to register a CAGR of 8.5% between 2026 and 2034.

Executive Summary and Europe Long-Term Injectable Drug Delivery Market Analysis:

The Europe Long-Term Injectable Drug Delivery Market, covering the UK, Germany, France, Italy, Spain, and the Rest of Europe, is witnessing sustained growth as healthcare providers increasingly seek treatment approaches that offer prolonged therapeutic effects and greater patient convenience. The rising burden of chronic diseases, including diabetes, cancer, and cardiovascular conditions, is generating demand for drug delivery systems capable of administering medication over extended periods. Compared with daily oral or short-duration treatments, long-acting injectable therapies can reduce dosing frequency and help patients maintain greater consistency with their treatment plans.

Europe's aging population is another significant factor supporting market development. Older individuals frequently manage multiple chronic conditions and may benefit from simplified medication schedules and reliable delivery mechanisms. At the same time, advances in pharmaceutical formulation technologies, including depot injections, biodegradable polymers, and controlled-release systems, are improving the duration, safety, and effectiveness of injectable therapies.

The region's well-developed healthcare infrastructure and established regulatory environment provide a favorable foundation for the introduction of innovative drug delivery technologies. Increasing healthcare expenditure and government initiatives focused on improving treatment outcomes are also encouraging the adoption of long-acting therapies. Pharmaceutical and biotechnology companies are increasing research and development efforts to develop improved injectable formulations, particularly for areas such as diabetes, mental health, hormone-related conditions, and other chronic diseases.

The growing emphasis on patient-centered healthcare is further strengthening demand for convenient treatment options. As healthcare systems seek to reduce treatment interruptions, improve adherence, and manage the increasing burden of chronic diseases, long-term injectable delivery technologies are expected to play a progressively important role across Europe.

Strategic Insights

Europe Long-Term Injectable Drug Delivery Market Segmentation Analysis:

By Formulation Packaging (Ready-to-Use), the Europe Long-Term Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment dominated the market in 2025.

By Therapeutic Application, the market is divided into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Others. Diabetes represented the largest segment in 2025.

By Route of Administration, the market comprises Subcutaneous, Intramuscular, Intravenous, and Others. The Subcutaneous segment held the dominant position in 2025.

By Usability, the market is categorized into Disposable Injectors and Re-usable Injectors. Disposable Injectors accounted for the largest share in 2025.

By End User, the market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. Pharmaceutical and Biopharma Companies led the market in 2025.

Market Report Scope

Europe Long-Term Injectable Drug Delivery Market Outlook

Medication non-adherence remains a major challenge in the treatment of chronic and psychiatric conditions, creating strong demand for delivery technologies that can reduce administration frequency and simplify treatment routines. The World Health Organization (WHO) has previously indicated that adherence to long-term therapies for chronic diseases averages approximately 50% in developed countries. Poor adherence can contribute to worsening disease, increased hospital admissions, higher healthcare expenditure, and reduced treatment effectiveness. The problem is particularly significant in psychiatric care, where patients with schizophrenia and other severe mental illnesses may have substantial difficulties maintaining daily medication schedules.

Long-acting injectable (LAI) therapies provide an alternative by replacing frequent oral dosing with injections administered at intervals that can range from several weeks to several months, depending on the formulation. This approach can reduce the impact of missed doses and allow healthcare professionals to monitor treatment delivery more effectively.

Evidence from clinical and real-world studies continues to demonstrate the potential benefits of LAIs. A study published in February 2026 examining long-acting injectable antipsychotics in schizophrenia spectrum disorders reported substantial reductions in psychiatric hospitalization and relapse following treatment transition. Earlier research has also demonstrated the potential of long-acting aripiprazole to reduce hospitalization risk among individuals with early-phase schizophrenia.

Long-acting therapies are also relevant outside psychiatric care. Cabotegravir and rilpivirine, marketed as Cabenuva, provide an extended-interval treatment option for HIV, reducing reliance on daily oral antiretroviral medication. Similarly, extended-release naltrexone, marketed as Vivitrol, offers monthly administration for opioid dependence treatment.

By reducing the need for daily medication decisions and minimizing the possibility of forgotten doses, long-term injectable systems can contribute to improved adherence and more consistent drug exposure. Controlled release may also help reduce fluctuations in drug concentrations, supporting therapeutic stability. With chronic disease prevalence increasing and healthcare systems placing greater emphasis on patient-centered treatment, long-acting injectables are expected to remain an important component of modern drug delivery strategies.

Europe Long-Term Injectable Drug Delivery Market Country Insights

By country, the Europe Long-Term Injectable Drug Delivery Market is segmented into Germany, the United Kingdom, France, Spain, Italy, and the Rest of Europe. The Rest of Europe held the largest market share in 2025.

Countries including Norway, Denmark, Sweden, Poland, Switzerland, the Netherlands, and Belgium represent important contributors within the Rest of Europe segment. The prevalence of chronic diseases across these countries creates sustained demand for treatment approaches that can provide reliable and extended drug delivery.

Diabetes remains a significant area of application. IDF-aligned estimates indicate substantial diabetic populations in countries such as Poland, the Netherlands, Denmark, and Norway, while Switzerland and Belgium also report notable prevalence among adults. Long-acting injectable technologies, including extended-duration insulin and GLP-1-based therapies, can reduce the frequency and daily burden associated with treatment.

The European regulatory environment is also supporting innovation in long-acting therapies. During 2025, European regulatory developments included recommendations and authorizations related to twice-yearly subcutaneous HIV pre-exposure prophylaxis, while long-acting cabotegravir and rilpivirine treatment options have continued to expand into younger patient populations.

Healthcare systems across countries such as Denmark and the Netherlands are also emphasizing community-based and patient-focused care models, creating opportunities for sustained-release therapies. Poland and Belgium are working to strengthen access to chronic disease management, while Switzerland and Norway continue to integrate advanced treatments within well-developed healthcare systems.

Collectively, these developments demonstrate how improvements in pharmaceutical formulations, regulatory approvals, and healthcare delivery models are supporting the broader adoption of long-term injectable therapies. By reducing administration frequency and improving treatment convenience, these systems can help address the needs of diverse patient populations across Europe's healthcare landscape.

Europe Long-Term Injectable Drug Delivery Market Company Profiles

Key companies operating in the Europe Long-Term Injectable Drug Delivery Market include Terumo Corp, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Schott AG, AptarGroup Inc, Becton Dickinson and Co, Owen Mumford Ltd, and SHL Medical.

These market participants are pursuing strategies including geographic expansion, product innovation, research and development, strategic partnerships, manufacturing expansion, and mergers and acquisitions. Through these initiatives, companies are working to strengthen their injectable delivery portfolios, improve device usability, develop advanced drug delivery technologies, and increase their presence in the growing European market.

Product Code: TIPRE00044021

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Long-Term Injectable Drug Delivery Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Europe Long-Term Injectable Drug Delivery Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Long-Term Injectable Drug Delivery Market - Europe Analysis

5.1 Europe Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021 - 2034
5.2 Europe Long-Term Injectable Drug Delivery Market Revenue Forecast and Analysis

6. Europe Long-Term Injectable Drug Delivery Market Revenue Analysis - by Formulation Packaging (ready-to-use)

6.1 Europe Long-Term Injectable Drug Delivery Market Forecast and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
  - 6.1.1.1 Overview
  - 6.1.1.2 Ampoules: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Vials
  - 6.1.2.1 Overview
  - 6.1.2.2 Vials: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.3 Cartridges
  - 6.1.3.1 Overview
  - 6.1.3.2 Cartridges: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.4 Bottles
  - 6.1.4.1 Overview
  - 6.1.4.2 Bottles: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. Europe Long-Term Injectable Drug Delivery Market Revenue Analysis - by Therapeutic Application

7.1 Europe Long-Term Injectable Drug Delivery Market Forecast and Analysis by Therapeutic Application
- 7.1.1 Diabetes
  - 7.1.1.1 Overview
  - 7.1.1.2 Diabetes: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Oncology
  - 7.1.2.1 Overview
  - 7.1.2.2 Oncology: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
  - 7.1.3.1 Overview
  - 7.1.3.2 Auto-Immune Disorders: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Cardiovascular Diseases: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Infectious Diseases
  - 7.1.5.1 Overview
  - 7.1.5.2 Infectious Diseases: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.6 Pain Management
  - 7.1.6.1 Overview
  - 7.1.6.2 Pain Management: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.7 Others
  - 7.1.7.1 Overview
  - 7.1.7.2 Others: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. Europe Long-Term Injectable Drug Delivery Market Revenue Analysis - by Route Of Administration

8.1 Europe Long-Term Injectable Drug Delivery Market Forecast and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
  - 8.1.1.1 Overview
  - 8.1.1.2 Subcutaneous: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Intramuscular
  - 8.1.2.1 Overview
  - 8.1.2.2 Intramuscular: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Intravenous
  - 8.1.3.1 Overview
  - 8.1.3.2 Intravenous: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.4 Others
  - 8.1.4.1 Overview
  - 8.1.4.2 Others: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. Europe Long-Term Injectable Drug Delivery Market Revenue Analysis - by Usability

9.1 Europe Long-Term Injectable Drug Delivery Market Forecast and Analysis by Usability
- 9.1.1 Disposable Injectors
  - 9.1.1.1 Overview
  - 9.1.1.2 Disposable Injectors: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 9.1.2 Re-usable Injectors
  - 9.1.2.1 Overview
  - 9.1.2.2 Re-usable Injectors: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

10. Europe Long-Term Injectable Drug Delivery Market Revenue Analysis - by End User

10.1 Europe Long-Term Injectable Drug Delivery Market Forecast and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
  - 10.1.1.1 Overview
  - 10.1.1.2 Pharmaceutical and Biopharma Companies: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
  - 10.1.2.1 Overview
  - 10.1.2.2 CMOs and CDMOs: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

11. Europe Long-Term Injectable Drug Delivery Market - Country Analysis

11.1 Europe
- 11.1.1 Europe Long-Term Injectable Drug Delivery Market Forecast and Analysis - by Country
  - 11.1.1.1 Germany Market
    - 11.1.1.1.1 Germany: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.1.2 Germany: Europe Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.1.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.1.2.2 Therapeutic Application
      - 11.1.1.1.2.3 Route Of Administration
      - 11.1.1.1.2.4 Usability
      - 11.1.1.1.2.5 End User
  - 11.1.1.2 United Kingdom Market
    - 11.1.1.2.1 United Kingdom: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.2.2 United Kingdom: Europe Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.2.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.2.2.2 Therapeutic Application
      - 11.1.1.2.2.3 Route Of Administration
      - 11.1.1.2.2.4 Usability
      - 11.1.1.2.2.5 End User
  - 11.1.1.3 France Market
    - 11.1.1.3.1 France: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.3.2 France: Europe Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.3.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.3.2.2 Therapeutic Application
      - 11.1.1.3.2.3 Route Of Administration
      - 11.1.1.3.2.4 Usability
      - 11.1.1.3.2.5 End User
  - 11.1.1.4 Spain Market
    - 11.1.1.4.1 Spain: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.4.2 Spain: Europe Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.4.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.4.2.2 Therapeutic Application
      - 11.1.1.4.2.3 Route Of Administration
      - 11.1.1.4.2.4 Usability
      - 11.1.1.4.2.5 End User
  - 11.1.1.5 Italy Market
    - 11.1.1.5.1 Italy: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.5.2 Italy: Europe Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.5.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.5.2.2 Therapeutic Application
      - 11.1.1.5.2.3 Route Of Administration
      - 11.1.1.5.2.4 Usability
      - 11.1.1.5.2.5 End User
  - 11.1.1.6 Rest of Europe Market
    - 11.1.1.6.1 Rest of Europe: Europe Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.6.2 Rest of Europe: Europe Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.6.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.6.2.2 Therapeutic Application
      - 11.1.1.6.2.3 Route Of Administration
      - 11.1.1.6.2.4 Usability
      - 11.1.1.6.2.5 End User

12 Long-Term Injectable Drug Delivery Market Industry Landscape

13 - Key Company Profiles

13.1 Terumo Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Phillips-Medisize
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Gerresheimer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 West Pharmaceutical Services Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Ypsomed Holding AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Schott AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AptarGroup Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Becton Dickinson and Co
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SHL Medical
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 Glossary
14.2 Research Methodology and Approach
- 14.2.1 Secondary Research
- 14.2.2 Primary Research
- 14.2.3 Market Estimation Approach
  - 14.2.3.1 Supply Side Analysis
  - 14.2.3.2 Demand Side Analysis
- 14.2.4 Research Assumptions and Limitations
- 14.2.5 Currency Conversion
14.3 About The Insight Partners
14.4 Market Intelligence Cloud